AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer

Current Opinion in Investigational Drugs

Volumn 9, Issue 6, 2008, Pages 638-646

  Tamm, I ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AEG 35156; AEG 35192; ALICAFORSEN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; CYTARABINE; DOCETAXEL; DRUG METABOLITE; GEMCITABINE; IDARUBICIN; MITOXANTRONE; MONOCLONAL ANTIBODY; NVP LBW 242; OBLIMERSEN; OGX 011; PACLITAXEL; SM 164; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TOLERABILITY; ENTERITIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEOPLASM; NONHUMAN; PANCREAS CANCER; PATENT; RECURRENT CANCER; REVIEW; SIDE EFFECT; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TOXICITY TESTING; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PATENTS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 44649097840     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. 296420 Isis and Ciba vision receive FDA approval for CMV retinitis drug. ISIS Pharmaceuticals Inc PRESS RELEASE 1998 August 27
2. 427209 Antisense therapy in oncology: New hope for an old idea? Tamm I, Dörken B, Hartmann G LANCET 2001 358 9280 489-497
3. 446279 Antisense oligonucleotides targeting XIAP induce apoptosis and enhance therapeutic activity against human lung cancer cells when combined with anticancer drug in vitro and in vivo. Hu Y, Dragowska V, Korneluk R, Cherton-Horvat G, Durkin J, Lacasse E, Mayer L PROC AM ASSOC CANCER RES 2002 43 Abs 2856
4. 464176 Hybridon and Aegera enter antisense pact. Hybridon Inc, Aegera Therapeutics Inc PRESS RELEASE 2002 September 17
5. 497131 Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD, LaCasse EC CLIN CANCER RES 2003 9 7 2826-2836
6. 509573 Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Sasaki H, Sheng Y, Kotsuji F, Tsang B CANCER RES 2000 60 20 5659-5666
7. 529304 Aegera starts phase I oncology trial of XIAP inhibitor. Aegera Therapeutics Inc, Hybridon Inc PRESS RELEASE 2004 March 29
8. 530761 The XIAP antisense compound AEG35156/GEM640 demonstrates significant antitumour activity in multiple human cancer xenograft models. Lacasse E, McManus D, Cherton-Horvat G, Wang H, Kandimalla E, Zhang R, Agrawal S, Batist G, Kandouz M, Vanderhyden B, Shaw T PROC AM ASSOC CANCER RES 2004 45 Abs 2947
9. 530763 Pharmacokinetic, toxicity and safety pharmacology profiles of AEG35156/GEM640, a XIAP antisense compound, in cynomolgus monkeys. Winocour P, Vezina M, Kornbrust D, Sullivan T, Durkin J PROC AM ASSOC CANCER RES 2004 45 Abs 2953
10. 591608 A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Ambrosini G, Adida C, Altieri DC NAT MED 1997 3 8 917-921
11. 624351 Aegera starts AEG-35156 phase I study in solid tumors. Aegera Therapeutics Inc PRESS RELEASE 2005 September 21
12. 635647 Anti-tumor activity of XIAP antisense compound, AEG35156, correlates with suppression of XIAP mRNA and protein levels in human cancer models. LaCasse E, Cherton-Horvat G, Lefebvre C, St Jean M, Hewitt K, Lussier J, Méthot D, Jerome L, Winocour P, Gillard J, Durkin J CLIN CANCER RES 2005 11 23 suppl Abs A 40
13. 635776 A phase I trial of AEG35156 (XIAP antisense) administered as a 7-day continuous intravenous infusion in patients with advanced tumors. Ranson M, Dive C, Ward T, Cummings J, Connolly K, Evans S, Robson L, Durkin J, Jolivet J, Jodrell D CLIN CANCER RES 2005 11 23 suppl Abs C72
14. 659015 AEG35156, a XIAP antisense oligonucleotide, suppresses XIAP levels in targeted tissues isolated from pre-clinical models and from patients. LaCasse E, Morris S, Ward T, Cumings J, Robson L, Di Tullio K, Méthot D, Jerome L, Winocour P, Gillard JW, Jolivet J et al PROC AM ASSOC CANCER RES 2006 47 Abs 4862
15. 670952 A phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors. Ranson M PROC AM SOC CLIN ONCOL 2006 25 Abs 3059
16. 688079 In vitro and in vivo activity of 2′-O-alkyl-4′-thio modified antisense oligonucleotides. Prakash TP, Dande P, Siwkowski AM, Lee S, Gaus HJ, Swayze EE, Bhat B ACS MEETING 2006 232 MEDI-233
17. 729398 Challenge and promise: Roles for clusterin in pathogenesis, progression and therapy of cancer. Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W, Reichrath J CELL DEATH DIFFER 2006 13 1 12-19
18. 736028 Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. LaCasse EC, Cherton-Horvat GG, Hewitt KE, Jerome LJ, Morris SJ, Kandimalla ER, Yu D, Wang H, Wang W, Zhang R, Agrawal S et al CLIN CANCER RES 2006 12 17 5231-5241
19. 736029 Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Cummings J, Ward TH, LaCasse E, Lefebvre C, St-Jean JM, Durkin J, Ranson M, Dive C BR J CANCER 2005 92 3 532-538 • This is the first paper on the validation of pharmacodynamic assays to be used in phase I clinical trials of AEG-35156.
20. 736030 Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. McManus DC, Lefebvre CA, Cherton-Horvat G, St-Jean M, Kandimalla ER, Agrawal S, Morris SJ, Durkin JP, Lacasse EC ONCOGENE 2004 23 49 8105-8117 • This paper described the killing effects of XIAP knock-down in various cell lines.
21. 736031 Down-regulation of inhibitor-of-apoptosis proteins sensitizes cancer cells to cytokine-induced cell death. Lefebvre CA, McManus DC, Cherton HG, St Jean M, Baird S, Liston P, Korneluk RG, Kandimalla E, Agrawal S, Durkin JP PROC AM ASSOC CANCER RES 2003 94 Abs 626
22. 739443 Comparison of cell death ELISAs applied as potential surrogate biomarkers in the clinical evaluation of AEG35156 (XIAP antisense). Cummings J CLINICAL CANCER RESEARCH 2006 4 12 Abs 143
23. 740083 EORTC-NCI-AACR - 18th symposium (Part I) - OVERNIGHT REPORT, Molecular targets and cancer therapeutics, Prague, Czech Republic. Kibble A IDDB MEETING REPORT 2006 November 7-10
24. 772115 Atlantic licenses exclusive rights to Isis' alicaforsen. Isis Pharmaceuticals Inc PRESS 2007 March 08
25. 773763 Enzo therapeutics treats first patient in phase I/II study of antisense gene therapy for HIV-1 infections. Enzo Therapeutics Inc PRESS RELEASE 2007 March 13
26. 803139 NCT00363974: Study of XIAP antisense given with chemotherapy for refractory/relapsed AML. Aegera Therapeutics WWW.CLINICALTRIALS.GOV 2006 August 10
27. 803142 NCT00372736: AEG35156 and docetaxel in treating patients with locally advanced, metastatic, or recurrent solid tumors. National Cancer Institute (NCI) WWW.CLINICALTRIALS.GOV 2007 June 06
28. 803200 NCT00385775: Study of XIAP antisense for advanced cancers. Aegera Therapeutics WWW.CLINICALTRIALS.GOV 2006 October 06
29. 835798 Aegera initiates four phase I/II trials of AEG-35156 for cancer. Aegera Therapeutics Inc PRESS RELEASE 2007 October 03
30. 835850 Company website. Aegera Therapeutics Inc COMPANY WORLD WIDE WEB SITE 2007 October 03
31. 837561 The inhibitor of apoptosis protein family and its antagonists in acute leukemias. Wrzesien-Kus A, Smolewski P, Sobczak-Pluta A, Wierzbowska A, Robak T APOPTOSIS 2004 9 6 705-715
32. 840658 Frontiers in CNS and oncology medicinal chemistry - Third international ACS/EFMC meeting (part II), Siena, Italy. Rotella DP IDDB MEETING REPORT 2007 October 07-09
33. 845409 Cell death ELISAs in the phase I clinical evaluation of AEG35156 (XIAP antisense) administered as an intravenous infusion over 7-days, 3-days, and 2-hours. Ranson M, Dean E, Ward T, Cummings J, Robson L, Durkin J, Jolivet J, Jodrell J, Dive D AACRNCI-EORTC INT CONGRESS 2007 19 October 24 Abs C163
34. 845676 In vivo tumor regression achieved by a potent bivalent Smac mimetic (SM-164) in combination with TRAIL. Lu J, Sun H, McEachern D, Miller R, Qiu S, Yi H, Nikolovska-Coleska Z, Yang D, Wang S AACR-NCIEORTC INTERNATIONAL CONGRES 2007 19 October 25 Abs C228
35. 860164 Addition of Oblimersen (Bcl-2 antisense) to fludarabine/cyclophosphamide for relapsed/refractory chronic lymphocytic leukemia extends survival in patients who achieve CR/nPR: Results from a randomized phase 3 study. O'Brien S, Moore J, Ding L AM SOC HEMATOL ANN MEET EXPOSITION 2007 49 December 11 Abs 751
36. 861981 Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Cummings J, Ranson M, Lacasse E, Ganganagari JR, St-Jean M, Jayson G, Durkin J, Dive C BR J CANCER 2006 95 1 42-48
37. 863004 FDA to extend review of data quality submission for Genasense(R) in melanoma. Genta Inc PRESS RELEASE 2007 December 21
38. 877169 OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in phase 2 trial with second-line chemotherapy for prostate cancer. OncoGenex Technologies Inc PRESS RELEASE 2008 February 15
39. 883153 Downregulation of XIAP expression in ovarian cancer cells induces cell death in vitro and in vivo. Shaw TJ, Lacasse EC, Durkin JP, Vanderhyden BC INT J CANCER 2008 122 6 1430-1434
40. 885037 Genta incorporated announces fourth quarter and year end 2007 financial results and corporate highlights. Genta Incorporated PRESS RELEASE 2008 March 12
41. 886886 FDA rejects Genta's appeal against Genasense non-approvable letter. Genta Inc PRESS RELEASE 2008 March 17
42. 894244 Application of XIAP antisense to cancer and other proliferative disorders: Development of AEG35156/ GEM640. Lacasse EC, Kandimalla ER, Winocour P, Sullivan T, Agrawal S, Gillard JW, Durkin J ANN NY ACAD SCI 2005 1058 215-234
43. 894386 Human inhibitor of apoptosis proteins: Why XIAP is the black sheep of the family. Eckelman BP, Salvesen GS, Scott FL EMBO REP 2006 7 10 988-994
44. 894401 Many cuts to ruin: A comprehensive update of caspase substrates. Fischer U, Jänicke RU, Schulze-Osthoff K CELL DEATH DIFFER 2003 10 1 76-100
45. 894464 Bypassing bypass surgery and other success stories from the National Institutes of Health. Nijhara R, Tidwell JL, Ferguson S, Balakrishnan K AUTM JOURNAL 2005 17 2 1-16
46. 894645 NCT00620321: A study of LY2181308 in patients with relapsed or refractory acute myeloid leukaemia. WWW.CLINICALTRIALS. GOV 2008 February 04
47. 894647 NCT00642018: A study of an experimental chemotherapy combination to treat hormone refractory prostate cancer. WWW.CLINICALTRIALS.GOV 2008 February 2008
48. 894665 Reprieval from execution: The molecular basis of caspase inhibition. Stennicke HR, Ryan CA, Salvesen GS TRENDS BIOCHEM SCI 2002 27 2 94-101
49. 894667 XIAP, the guardian angel. Holcik M, Korneluk RG NAT REV MOL CELL 2001 2 7 550-556
50. 894670 XIAP: Apoptotic brake and promising therapeutic target. Holcik M, Gibson H, Korneluk RG APOPTOSIS 2001 6 4 253-261
51. 894673 Apoptosis: Implications of basic research for clinical oncology. Tamm I, Schriever F, Dörken B LANCET ONCOL 2001 2 1 33-42
52. 894676 Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Zhang XD, Zhang XY, Gray CP, Nguyen T, Hersey P CANCER RES 2001 61 19 7339-7348
53. 894677 Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ, Pedersen IM, Kitada S, Scott FL, Bailly-Maitre B, Glinsky G et al CANCER CELL 2004 5 1 25-35
54. 894682 Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistance TCC in vitro. Bilim V, Kasahara T, Hara N, Takahashi K, Tomita Y INT J CANCER 2003 103 1 29-37
55. 894683 X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cummins JM, Kohli M, Rago C, Kinzler KW, Vogelstein B, Bunz F CANCER RES 2004 64 9 3006-3008
56. 894685 How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Workman P CURR PHARM DESIGN 2003 9 11 891-892
57. 894691 Bioanalytical method validation - a revisit with a decade of progress. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A et al PHARM RES 2000 17 12 1551-1557
58. 894692 Workshop on bioanalytical methods validation for macromolecules: Summary report. Miller KJ, Bowsher RR, Celniker A, Gibbons J, Gupta S, Lee JW, Swanson SJ, Smith WC, Weiner RS PHARM RES 2001 18 9 1373-1383
59. 895753 X-linked inhibitor of apoptosis protein as a therapeutic target. Dean EJ, Ranson M, Blackhall F, Dive C EXPERT OPIN THER TARGETS 2007 11 11 1459-1471
60. 895756 High expression levels of X-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Tamm I, Richter S, Oltersdorf D, Creutzig U, Harbott J, Scholz F, Karawajew L, Ludwig WD, Wuchter C CLIN CANCER RES 2004 10 11 3737-3744
61. 895759 Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Hinnis AR, Luckett JC, Walker RA BR J CANCER 2007 96 4 639-645
62. 895763 Antisense therapy in malignant diseases: Status quo and quo vadis? Tamm I CLIN SCI (LOND) 2006 110 4 427-442
63. 895764 Antisense oligonucleotides: An evolving technology for the modulation of gene expression in human disease. Green DW, Roh H, Pippin J, Drebin JA J AM COLL SURG 2000 191 1 93-105
64. 895766 2′-Modified oligonucleotides for antisense therapeutics. Prakash TP, Bhat B CURR TOP MED CHEM 2007 7 7 641-649
65. 898806 NCT00557596: A phase 1-2, XIAP antisense AEG35156 with gemcitabine in patients with advanced pancreatic cancer. Aegera Therapeutics CLINICALTRIALS.GOV 2007 November 13
66. 898807 NCT00558545: A phase 1-2, XIAP antisense AEG35156 with weekly paclitaxel in patients with advanced breast cancer. Aegera Therapeutics CLINICALTRIALS.GOV 2007 November 13
67. 898808 NCT00558922: A phase 1-2 XIAP antisense AEG35156 with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Aegera Therapeutics CLINICALTRIALS.GOV 2007 November 13
68. 898824 Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway. Srinivasula SM, Datta P, Fan XJ, Fernandes-Alnemri T, Huang Z, Alnemri ES J BIOL CHEM 2000 275 46 36152-36157